Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
The present invention generally relates to a novel therapeutical use of liver X receptor (LXR) agonsits. More specifically, the present invention relates to the use of LXR agonist for the preparation of a medicament useful for the treatment and/or the prevention of a disease associated with beta cells degeneration, such as diabetes, and a method for increasing ex vivo viability of pancreatic islet cells, comprising contacting said islet cells with a LXR agonist.
patent: 6316503 (2001-11-01), Li et al.
patent: 6924311 (2005-08-01), Schulman et al.
patent: 2003/0073614 (2003-04-01), Schulman et al.
patent: 2005/0036992 (2005-02-01), Saez et al.
patent: 1 398 032 (2004-03-01), None
patent: WO 90/11296 (1990-10-01), None
patent: WO 98/43658 (1998-10-01), None
patent: WO 99/43705 (1999-09-01), None
patent: WO 01/41704 (2001-06-01), None
patent: WO 2006/094034 (2006-09-01), None
Cao et al., “Antidiabetic Action of a Liver X Receptor Agonist Mediated By Inhibition of Hepatic Gluconeogenesis”, The Journal of Biological Chemistry, vol. 278, No. 2, pp. 1131-1136 (2003).
Beers et al., The Merck Manual of Medical Information, 2nd Home Edition, pp. 968 and 969 (2003).
International Search Report, dated Mar. 30, 2007 (PCT/ISA/210) including PCT/ISA/220 and PCT/ISA/237 (Ten (10) pages).
Efanov, A. M. et al., “Liver X Receptor Activation Stimulates Insulin Secretion via Modulation of Glucose and Lipid Metabolism in Pancreatic β-Cells”, Diabetes, Dec. 2004, pp. S75-S78, vol. 53, Supplement 3.
Steffensen, K. R. et al., “Section II: Nuclear Receptors and Islet Function—Putative Metabolic Effects of the Liver X Receptor (LXR)”, Diabetes, Feb. 2004, pp. S36-S42, vol. 53, Supplement 1.
Cao, G. et al., “Antidiabetic Action of a Liver X Receptor Agonist Mediated by Inhibition of Heptic Gluconeogenesis”, The Journal of Biological Chemistry, Jan. 10, 2003, pp. 1131-1136, vol. 278, No. 2.
Menke, J. G. et al., “A Novel Liver X Receptor Agonist Establishes Species Differences in the Regulation of Cholesterol 7 α-Hydroxylase (CYP7a)”, Endocrinology, 2002, pp. 2548-2558, vol. 143, No. 7.
Janowski, B. A. et al., “An oxysterol signaling pathway mediated by the nuclear receptor LXRα”, Nature, Oct. 24, 1996, pp. 728-731, vol. 383.
Schultz, J. R. et al., “Role of LXRs in control of lipogenesis”, Genes and Development, 2000, pp. 2831-2838, vol. 14.
Joseph, S. B. et al., “Synthetic LXR ligand inhibits the development of atherosclerosis in mice”, PNAS, May 28, 2002, pp. 7604-7609, vol. 99, No. 11.
Collins, J. L. et al., “Identification of a Nonsteroldal Liver X Receptor Agonist through Parallel Array Synthesis of Tertiary Amines”, J. Med. Chem., 2002, pp. 1963-1966, vol. 45.
Janowski, B. A. et al., “Structural requirements of ligands for the oxysterol liver X receptors LXRα and LXRβ”, Proc. Natl. Acad. Sci., Jan. 1999, pp. 266-271, vol. 96, Pharmacology.
Berger, J. et al., “Novel Peroxisome Proliferator-activated Receptor (PPAR) γ and PPAR6 Ligands Produce Distinct Biological Effects”, The Journal of Biological Chemistry, Mar. 5, 1999, pp. 6718-6725, vol. 274, No. 10.
Spencer, T. A. et al., “Pharmacophore Analysis of the Nuclear Oxysterol Receptor LXRα”, J. Med. Chem, 2001, pp. 886-897, vol. 44.
Sparrow, C. P. et al., “A Potent Sythetic LXR Agonist Is More Effective than Cholesterol Loading at Inducing ABCA1 mRNA and Stimulating Cholesterol Efflux”,. The Journal of Biological Chemistry, Mar. 22, 2002, pp. 10021-10027, vol. 277, No. 12.
Liao, K. et al., “The Blockade of Preadipocyte Differentiation by Protein-tyrosine Phosphatase HA2 Is Reversed by Vanadate”, The Journal of Biological Chemistry, May 19, 1995, pp. 12123-12132, vol. 270, No. 20.
Efanov et al., “Liver X Receptor Activation Stimulates Insulin Secretion via Modulation of Glucose and Lipid Metabolism in Pancreatic Beta-Cells,” Diabetes, vol. 53, Supplement 3. Dec. 2004, S75-S78.
Chisholm et al., “The LXR ligand T0901317 induces severe lipogenesis in the db/db diabetic mouse,” Journal of Lipid Research, vol. 44, 2003, 2039-2048.
Crowell & Moring LLP
Laboratoires Fournier S.A.
Weddington Kevin E
Use of liver X receptor agonists does not yet have a rating. At this time, there are no reviews or comments for this patent.If you have personal experience with Use of liver X receptor agonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of liver X receptor agonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4285272